These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. [Efficacy of infliximab in treatment on inflammatory bowel disease and factors affecting the therapeutic effect]. Zhou Y; Chen Y Nan Fang Yi Ke Da Xue Xue Bao; 2013 Dec; 33(12):1833-8. PubMed ID: 24369257 [TBL] [Abstract][Full Text] [Related]
10. Use of Biosimilars in Paediatric Inflammatory Bowel Disease: A Position Statement of the ESPGHAN Paediatric IBD Porto Group. de Ridder L; Waterman M; Turner D; Bronsky J; Hauer AC; Dias JA; Strisciuglio C; Ruemmele FM; Levine A; Lionetti P; J Pediatr Gastroenterol Nutr; 2015 Oct; 61(4):503-8. PubMed ID: 26154031 [TBL] [Abstract][Full Text] [Related]
11. [How to Optimally Use Currently Available Drugs in a Therapeutic Algorithm?]. Kim YS Korean J Gastroenterol; 2018 Feb; 71(2):74-80. PubMed ID: 29471604 [TBL] [Abstract][Full Text] [Related]
12. [The up-to-date methods of management of NSAIDs-induced injuries of small intestine]. Tkach SM; Balabantseva HP; Levchenko AR Lik Sprava; 2014; (5-6):38-47. PubMed ID: 25906646 [TBL] [Abstract][Full Text] [Related]
13. Anti-inflammatory drug treatment of radiation injuries. Michalowski AS Adv Exp Med Biol; 1997; 400B():873-7. PubMed ID: 9547641 [No Abstract] [Full Text] [Related]
14. Antitumor necrosis factor, infliximab, and adalimumab: use with caution in eosinophilic bowel disease. Furuta GT; Atkins D; Capocelli KE; de Zoeten EF; Fleischer D; Menard-Katcher C J Pediatr Gastroenterol Nutr; 2013 Oct; 57(4):e25. PubMed ID: 23820407 [No Abstract] [Full Text] [Related]
15. Severe adverse reactions to Infliximab therapy are common in young children with inflammatory bowel disease. Kolho KL; Ruuska T; Savilahti E Acta Paediatr; 2007 Jan; 96(1):128-30. PubMed ID: 17187619 [TBL] [Abstract][Full Text] [Related]